BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 10:02:00 AM | Browse: 1218 | Download: 825
Publication Name World Journal of Biological Chemistry
Manuscript ID 9046
Country/Territory United States
Received
2014-01-18 18:13
Peer-Review Started
2014-01-18 20:02
To Make the First Decision
2014-02-13 16:18
Return for Revision
2014-02-20 23:51
Revised
2014-03-12 12:48
Second Decision
2014-05-14 16:29
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-14 16:42
Articles in Press
2014-05-23 08:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-08-29 15:16
Publish the Manuscript Online
2014-09-11 10:03
ISSN 1949-8454 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cell Biology
Manuscript Type Topic Highlights
Article Title In 2014, can we do better than CA125 in the early detection of ovarian cancer?
Manuscript Source Invited Manuscript
All Author List Joshua G Cohen, Matthew White, Ana Cruz and Robin Farias-Eisner
Funding Agency and Grant Number
Corresponding Author Robin Farias-Eisner M.D., Ph.D. UCLA Department of Obstetrics and Gynecology Peter Morton Medical Building 200 Medical Plaza, Suite 220 Los Angeles, CA 90095 Phone: (310) 206-8914 Fax: (310) 206-2057 Email address: RFEisner@mednet.ucla.edu
Key Words ovarian cancer; screening; biomarker; detection; diagnostic imaging; proteomics; adnexal mass
Core Tip Ovarian cancer is a lethal gynecologic malignancy with greater than 70% of women presenting with advanced stage disease. Despite new treatments, long term outcomes have not significantly changed in the past 30 years with the five-year overall survival remaining between 20 and 40% for stage III and IV disease. In contrast patients with stage I disease have a greater than 90% five-year overall survival. Detection of ovarian cancer at an early stage would likely have significant impact on mortality rate. Screening biomarkers discovered at the bench have not translated to success in clinical trials. Existing screening modalities have not demonstrated survival benefit in completed prospective trials. Advances in high throughput screening are making it possible to evaluate the development of ovarian cancer in ways never before imagined. Data in the form of human “–omes” including the proteome, genome, metabolome, and transcriptome are now available in various packaged forms. With the correct pooling of resources including prospective collection of patient specimens, integration of high throughput screening, and use of molecular heterogeneity in biomarker discovery, we are poised to make progress in ovarian cancer screening. This review will summarize current biomarkers, imaging, and multimodality screening strategies in the context of emerging technologies.
Publish Date 2014-09-11 10:03
Citation Cohen JG, White M, Cruz A, Farias-Eisner R. In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 2014; 5(3): 286-300
URL http://www.wjgnet.com/1949-8454/full/v5/i3/286.htm
DOI http://dx.doi.org/10.4331/wjbc.v5.i3.286
Full Article (PDF) WJBC-5-286.pdf
Full Article (Word) WJBC-5-286.doc
Manuscript File 9046-Review.doc
Answering Reviewers 9046-Answering reviewers.pdf
Copyright License Agreement 9046-Copyright assignment.pdf
Peer-review Report 9046-Peer review(s).pdf
Scientific Editor Work List 9046-Scientific editor work list.pdf